Relamorelin

Relamorelin
Clinical data
Routes of; administration	Subcutaneous
ATC code	None;
Identifiers
	IUPAC name 4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-Benzothiophen-3-yl)-2-(piperidine-3-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide;
CAS Number	661472-41-9;
PubChem CID	85364156;
ChemSpider	32699203;
UNII	BIW199E18V;
KEGG	D10660 ;
CompTox Dashboard (EPA)	DTXSID701032407 ;
Chemical and physical data
Formula	C43H50N8O5S
Molar mass	790.98 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc(cc1)C[C@@H](C(=O)NC2(CCNCC2)C(=O)N)NC(=O)[C@@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@@H](Cc5csc6c5cccc6)NC(=O)C7CCNCC7;
	InChI InChI=1S/C43H50N8O5S/c44-42(56)43(16-20-46-21-17-43)51-41(55)34(22-27-8-2-1-3-9-27)49-39(53)35(23-29-25-47-33-12-6-4-10-31(29)33)50-40(54)36(48-38(52)28-14-18-45-19-15-28)24-30-26-57-37-13-7-5-11-32(30)37/h1-13,25-26,28,34-36,45-47H,14-24H2,(H2,44,56)(H,48,52)(H,49,53)(H,50,54)(H,51,55)/t34-,35+,36+/m0/s1; Key:KUBPNVYPKPWGRJ-LIVOIKKVSA-N;

Relamorelin (INN, USAN) (developmental code names RM-131, BIM-28131, BIM-28163) is a synthetic peptide, centrally penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) which is under development by Allergan pharmaceuticals for the treatment of diabetic gastroparesis, chronic idiopathic constipation, and anorexia nervosa.^[1]^[2]^[3] It is a pentapeptide and an analogue of ghrelin with improved potency and pharmacokinetics.^[1]^[2] In humans, relamorelin produces increases in plasma growth hormone, prolactin, and cortisol levels,^[2]^[4] and, like other GHSR agonists, increases appetite.^[3] As of June 2015, relamorelin is in phase II clinical trials for diabetic gastroparesis and constipation.^[5] The United States Food and Drug Administration (FDA) has granted Fast Track designation to relamorelin for diabetic gastroparesis.^[6] The development of the drug is uncertain as the most recent mention of it was in a 2019 SEC filing from the drug manufacturer lists the drug's expected launch year as 2024, but not in subsequent filings or press releases.^[7]^[8]

Quick facts Clinical data, Routes ofadministration ...

Close

See also

Clinical data

Routes of administration	Subcutaneous
ATC code	None
Identifiers
IUPAC name 4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-Benzothiophen-3-yl)-2-(piperidine-3-carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]piperidine-4-carboxamide
CAS Number	661472-41-9
PubChem CID	85364156
ChemSpider	32699203
UNII	BIW199E18V
KEGG	D10660^Y
CompTox Dashboard (EPA)	DTXSID701032407
Chemical and physical data
Formula	C₄₃H₅₀N₈O₅S
Molar mass	790.98 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES c1ccc(cc1)C[C@@H](C(=O)NC2(CCNCC2)C(=O)N)NC(=O)[C@@H](Cc3c[nH]c4c3cccc4)NC(=O)[C@@H](Cc5csc6c5cccc6)NC(=O)C7CCNCC7
InChI InChI=1S/C43H50N8O5S/c44-42(56)43(16-20-46-21-17-43)51-41(55)34(22-27-8-2-1-3-9-27)49-39(53)35(23-29-25-47-33-12-6-4-10-31(29)33)50-40(54)36(48-38(52)28-14-18-45-19-15-28)24-30-26-57-37-13-7-5-11-32(30)37/h1-13,25-26,28,34-36,45-47H,14-24H2,(H2,44,56)(H,48,52)(H,49,53)(H,50,54)(H,51,55)/t34-,35+,36+/m0/s1 Key:KUBPNVYPKPWGRJ-LIVOIKKVSA-N